Large on-patent customer inventory destocking unresolved
One major customer's inventory destocking continues to impact CDMO revenues with no specific resumption timeline provided. Management declined to quantify impact or reversal timeline for FY27.
PPLPHARMA / Q3-FY26 / risks
Keep the risk register visible.
Piramal Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Slow regulatory approvals for Digwal facility expanding markets
ROW sevoflurane approvals from Digwal taking longer than anticipated (now 12-18 months timeline). Management adopted cautious pricing strategy to avoid margin dilution, resulting in slower-than-expected ramp-up.
Kenalog acquisition contingent payments tied to undisclosed milestones
$65M contingent consideration structure details not disclosed. Management deflected question on specific triggers and geographic sales breakdown, creating opacity around deal economics.
Rising competition in ROW sevoflurane from Chinese suppliers
Increased competition from Chinese suppliers in rest-of-world markets creating pricing pressure. Management chose not to be overly aggressive on price to protect margins, trading off revenue growth.